期刊
HYPERTENSION RESEARCH
卷 44, 期 7, 页码 740-755出版社
SPRINGERNATURE
DOI: 10.1038/s41440-021-00643-z
关键词
Hypertension treatment; Target organ damage; RAAS; Bispecific peptides; Preclinical and clinical studies
资金
- UGC
- ICMR [RBMH/CAR 1312018-19]
The RAAS is crucial for regulating blood pressure and vascular tone, but overactivation can lead to severe cardiovascular and renal complications, highlighting the need for safe and effective treatment options. Ongoing research focuses on developing novel therapies to inhibit RAAS and improve outcomes for patients with hypertension.
The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential cellular processes and leads to high blood pressure, oxidative stress, inflammation, fibrosis, and hypertrophy. Consequently, these conditions cause fatal cardiovascular and renal complications. Thus, the primary purpose of hypertension treatment is to diminish or inhibit overactivated RAAS. Currently available RAAS inhibitors have proven effective in reducing blood pressure; however, beyond hypertension, they have failed to treat end-target organ injury. In addition, RAAS inhibitors have some intolerable adverse effects, such as hyperkalemia and hypotension. These gaps in the available treatment for hypertension require further investigation of the development of safe and effective therapies. Current research is focused on the combination of existing and novel treatments that neutralize the angiotensin II type I (AT1) receptor-mediated action of the angiotensin II peptide. Preclinical studies of peptide- and nonpeptide-based therapeutic agents demonstrate their conspicuous impact on the treatment of cardiovascular diseases in animal models. In this review, we will discuss novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies. In addition, we will also highlight the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据